3.0
Feb 17, 2012
Former employee
Kenilworth, NJ
Recommend
CEO approval
Business Outlook
Pros
Superb colleagues, excellent drug development programs, amazing legacy, competitive compensation, institutional knowledge still high, excellent corporate citizens, overall management has very good intentions
Cons
patent cliff led to panicked decision making, under the heel of Wall Street, post Schering merger led to period of profound consolidation and ultimately down-sizing...few opportunities for professional growth, lacking a clear emerging markets strategy....China still seems like a mystery to upper management